PONTE VEDRA, Fla., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagshipLapiplasty®andAdductoplasty®Procedures, today announced that John T. Treace, Chief Executive Officer, and Mark L. Hair, Chief Financial Officer, will participate in a fireside chat at the UBS Global Healthcare Conference on Tuesday, November 12, 2024, beginning at approximately 11:45 am ET.
A live webcast and replay of the fireside chat will be available on the Company’s investors relations website athttps://investors.treace.com/.
Internet Posting of InformationTreace routinely posts information that may be important to investors in the “Investor Relations” section of its website atwww.treace.com. The Company encourages investors and potential investors to consult the Treace website regularly for important information about Treace.
About Treace Medical Concepts
Treace Medical Concepts, Inc. is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion and related midfoot deformities. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 67 million Americans, of which Treace estimates 1.1 million are annual surgical candidates. Treace has pioneered and patented the Lapiplasty®3D Bunion Correction®System – a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. To further support the needs of bunion patients, Treace has introduced its Adductoplasty®Midfoot Correction System, designed for reproducible surgical correction of midfoot deformities. The Company continues to expand its footprint in the foot and ankle market with the introduction of its SpeedPlateTM Rapid Compression Implants, an innovative fixation platform with broad versatility across Lapiplasty®and Adductoplasty®procedures, as well as other common bone fusion procedures of the foot. For more information, please visitwww.treace.com.
To learn more about Treace, connect with us onLinkedIn,X,FacebookandInstagram.
Contacts:Treace Medical ConceptsMark L. HairChief Financial Officermhair@treace.net(904) 373-5940
Investors:Gilmartin GroupVivian CervantesIR@treace.net
